17May 2022
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study

This post hoc analysis investigated the effect of dulaglutide on cardiovascular disease (CVD) risk factors in subgroups of participants at increased CVD risk in the AWARD‐11 study. Serum lipids and vital signs were assessed at baseline and 52 weeks. Data were analyzed as least-squares mean percent change from baseline for lipids, and least-squares represent a change from baseline for vital signs. Demographic and baseline clinical characteristics were balanced across doses within the CVD risk groups. In addition, systolic and diastolic blood pressure decreased up to 5.6 mm Hg and 1.6 mm Hg, respectively, and heart rate increased up to 2 beats per minute. This post hoc analysis suggests the magnitude of the favourable effects of dulaglutide 3.0 mg and 4.5 mg on several cardiometabolic CVD risk factors was similar to, if not greater than, those of dulaglutide 1.5 mg among participants with type 2 diabetes and increased CVD risk.

  • #endo-diabetology

Like

Save

Share